Takeda Pharmaceutical Co Ltd: 9-Month Financial Summary (Ended Dec 31, 2025)
Business Context and Reporting Period
This Form 6-K filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the nine-month period ended December 31, 2025 (April 1, 2025 to December 31, 2025). The report was filed on January 29, 2026. Takeda operates as a single operating segment focused on the research, development, manufacturing, and marketing of pharmaceutical products across six key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), Oncology, Vaccines, and Neuroscience.
Key Financial Metrics
| Metric | 9 Months Ended Dec 31, 2025 | 9 Months Ended Dec 31, 2024 | Change (AER) |
|---|---|---|---|
| Revenue | JPY 3,411.2 billion | JPY 3,528.2 billion | -3.3% |
| Operating Profit | JPY 422.4 billion | JPY 417.5 billion | +1.2% |
| Profit Before Tax | JPY 312.7 billion | JPY 282.4 billion | +10.7% |
| Net Profit (Attributable to Owners) | JPY 216.1 billion | JPY 211.1 billion | +2.4% |
| Basic EPS | JPY 137.31 | JPY 133.71 | +2.7% |
| Core Operating Profit | JPY 971.6 billion | JPY 1,006.3 billion | -3.4% |
| Core EPS | JPY 428 | JPY 443 | -3.3% |
| Total Assets | JPY 15,408.8 billion | JPY 14,248.3 billion (Mar 31, 2025) | +8.1% |
| Total Equity | JPY 7,644.1 billion | JPY 6,936.0 billion (Mar 31, 2025) | +10.2% |
| Cash & Equivalents | JPY 654.9 billion | JPY 385.1 billion (Mar 31, 2025) | +70.1% |
| Operating Cash Flow | JPY 966.9 billion | JPY 835.0 billion | +15.8% |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 3.3% primarily due to a 31.1% drop in the Neuroscience segment, driven by generic erosion of VYVANSE in the U.S. This was partially offset by growth in GI (+3.8%), Vaccines (+10.2%), and Oncology (+1.9%).
- Profitability: Despite lower revenue, Operating Profit increased 1.2% due to cost savings from the enterprise-wide efficiency program and a significant reduction in restructuring expenses (down JPY 68.6 billion). However, impairment losses on intangible assets increased by JPY 53.3 billion, including JPY 58.2 billion related to the gamma delta T-cell therapy platform.
- Balance Sheet: Total assets and equity increased significantly, largely driven by foreign currency translation effects due to the depreciation of the Japanese yen. Cash and cash equivalents rose by JPY 269.8 billion.
- Dividends: The company declared a second-quarter dividend of JPY 100.00 per share and projected a year-end dividend of JPY 100.00, totaling JPY 200.00 for the fiscal year ending March 31, 2026.
Guidance, Outlook, and Risks
Revised Full-Year Forecast (FY Ending March 31, 2026): Takeda revised its full-year forecast upward slightly compared to the October 2025 announcement, primarily due to favorable foreign exchange rate assumptions.
- Revenue: JPY 4,530.0 billion (Previous: JPY 4,500.0 billion).
- Operating Profit: JPY 410.0 billion (Previous: JPY 400.0 billion).
- Net Profit: JPY 154.0 billion (Previous: JPY 153.0 billion).
- Core Operating Profit: JPY 1,150.0 billion (Previous: JPY 1,130.0 billion).
Management Guidance (Constant Exchange Rate): The guidance for Core Revenue, Core Operating Profit, and Core EPS has been revised to a "low-single-digit % decline" from the previous "broadly flat" or "low-single-digit % decline" outlook.
Risks and Contingencies:
- Generic Erosion: Continued impact on VYVANSE sales in the U.S.
- Regulatory/Pricing: Headwinds from the Medicare Part D redesign and 340B program expansion in the U.S.
- FX Volatility: Significant impact on reported results due to yen depreciation; forecasts assume specific FX rates (e.g., USD/JPY at 157 for full year).
- Tariffs: Assumptions include potential 15% tariffs on pharmaceutical imports into the U.S. from the EU and Japan, though the impact is currently expected to be immaterial.
Investor Verification Checklist
- VYVANSE Trajectory: Verify the extent of generic erosion in the U.S. market and its impact on the Neuroscience segment for the remainder of the fiscal year.
- Impairment Charges: Review the details of the JPY 58.2 billion impairment charge related to the gamma delta T-cell therapy platform and the decision to discontinue related R&D.
- FX Sensitivity: Assess the sensitivity of the revised full-year forecast to further fluctuations in the USD/JPY exchange rate, given the significant reliance on favorable FX assumptions.
- Cost Savings Realization: Monitor the execution of the enterprise-wide efficiency program to ensure projected cost savings in SG&A and R&D are realized.
- Dividend Sustainability: Confirm the company's ability to maintain the projected JPY 200.00 annual dividend given the decline in Core Operating Profit.